Lead Icosavax program IVX-A12 is a Phase 3-ready VLP vaccine that protects against RSV and human metapneumovirus (hMPV), which currently has no vaccine. The acquisition agreement announcement ...

Recently reported positive durability data for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) at six-month timepoint. In December, Icosavax announced that data from its ...

the potential for the company’s VLP platform to result in safe and effective vaccines against infectious diseases, including IVX-121 for RSV and IVX-A12 for hMPV and RSV, and to be well suited ...

Subjects were administered a single dose of either IVX-A12 at the 300 µg combination dosage level (150 µg of RSV VLP (IVX-121) and 150 µg of hMPV VLP (IVX-241)), with or without MF59 ...

IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV), two leading causes of severe respiratory infection ...

SEATTLE, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines ...

The VLP that was used as an immunogen contained the fusion glycoprotein (F) and G protein of RSV, as well as the matrix (M) and nucleocapsid (NP) core proteins from the Newcastle disease virus (NDV).

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate. “IVX-A12 is a potential ...

IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP ...